

LISTEN TO THEIR LUNGS

And answer with PERFOROMIST® for wide and favorable coverage

Covered by Medicare Part B, Medicare Part D, and 89% of commercial plans without prior therapy restrictions. ^{1,2} See below for the Managed Care Plans available to you.



Indiana

	Epipen	Epipen Jr.	Twinject
Commercial	Coverage Status	Coverage Status	Coverage Status
Anthem Blue Cross & Blue Shield of Indiana (3 Tier Open)	Covered Without Restriction	Covered Without Restriction	Covered Without Restriction
CIGNA HealthCare Indiana (3 Tier Open)	Covered With Restriction (QL)	Covered With Restriction (QL)	Covered With Restriction (PA)
UnitedHealth Group, Inc. (Indiana) (3 Tier Open)	Covered With Restriction (QL)	Covered With Restriction (QL)	Covered With Restriction (QL)
WellPoint, Inc. (PARENT) (3 Tier Open)	Covered Without Restriction	Covered Without Restriction	Covered Without Restriction
State Medicaid	Coverage Status	Coverage Status	Coverage Status
· · · · · · · · · · · · · · · · · · ·	<u> </u>		30701290 012120
Indiana Medicaid	Covered Without Restriction	Covered Without Restriction	Covered Without Restriction
Indiana Medicaid Managed Medicaid	<u>-</u>	Covered Without Restriction Coverage Status	·
	Covered Without Restriction		Covered Without Restriction
Managed Medicaid	Covered Without Restriction Coverage Status	Coverage Status	Covered Without Restriction Coverage Status

Formulary data provided by Pinsonault Associates, LLC, May, 2011

Plan formularies will vary and are subject to change without notice. Please check directly with the health plan to determine the most up to date formulary information.

WARNING: ASTHMA-RELATED DEATH

Long-acting beta₂-adrenergic agonists (LABA) increase the risk of asthma-related death. Data from a large placebo-controlled US study that compared the safety of another long-acting beta₂-adrenergic agonist (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol is considered a class effect of LABA, including formoterol, the active ingredient in PERFOROMIST Inhalation Solution.

The safety and efficacy of PERFOROMIST in patients with asthma have not been established. All LABA, including PERFOROMIST,

are contraindicated in patients with asthma without use of a long-term asthma control medication.

